ASX Announcement

30 January 2026

OncoSil™ delivers strong early clinical results in Türkiye
83% of patients achieved surgical resection alongside standard chemotherapy

Sydney, Australia – 30 January 2026: OncoSil Medical Limited (ASX: OSL) ("OncoSil Medical" or "the Company"), a medical device company focused on localised treatments for patients with unresectable locally advanced pancreatic cancer (LAPC), is pleased to announce very significant surgical re-section rates achieved in Ankara Bilkent City Hospital, Türkiye for patients treated in a clinical setting with the OncoSil™ device in addition to standard-of-care chemotherapy.

Ankara Bilkent City Hospital is among the first centres in Türkiye to adopt the OncoSil™ device in clinical practice and represents a high-volume pancreatic cancer treatment centre with over 500 patients undergoing surgery between February 2019 to December 2024.[1] To date, six pancreatic cancer patients have been treated with the OncoSil™ device in addition to standard-of-care chemotherapy (FOLFIRINOX). Post-treatment analysis reported one Complete Response (16.6%), four Partial Responses (66.6%), and one case of Stable Disease (16.6%). Importantly, **five of the six patients (83%) subsequently underwent successful surgical resection with curative intent**.

Patients who undergo surgical resection following chemotherapy treatment in LAPC have significantly higher median overall survival compared with those patients who did not qualify for surgical re-section (35.3 months vs 16.3 months, $p < 0.001$).[2] Although surgical re-section rates vary from study to study, the literature supports a re-section rate of approximately 15% for LAPC patients receiving first-line Gemcitabine + Nab-Paclitaxel (Gem-Nab) and for those receiving FOLFIRINOX chemotherapy the re-section rate is approximately 26% (13% without radiotherapy).[3,4,5]

The re-section rate achieved thus far at Ankara Bilkent City Hospital is also materially higher than earlier use of the OncoSil™ device in patients, including the 2022 PANCO clinical trial results (24% overall re-section rate, where 80% of patients received Gem-Nab)[6].

Nigel Lange, CEO & Managing Director of OncoSil Medical, said:

"Achieving an 83% surgical resection rate in this early commercial experience is an exceptional outcome and highlights the potential of the OncoSil™ device to meaningfully change treatment pathways.

Pancreatic cancer patients who are initially deemed unresectable typically have very limited options, with published resection rates remaining relatively low despite advances in chemotherapy.

OncoSil™'s outstanding results in this institution strongly support our commercial strategy and reinforces the long-term value proposition for shareholders."

OncoSil Medical continues to expand commercial adoption of the OncoSil™ device across international markets while building real-world clinical evidence to support broader use.

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of OncoSil Medical Limited.

For further information, please contact:

Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 30 300 149 3043	**Mr. Tim Luscombe & Mr. David Wood** Joint Company Secretaries E: tim.luscombe@bio101.com david.wood@bio101.com T: +61 429 707 079 & +61 408 393 670	**Ms. Julia Maguire** **The Capital Network** Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 7257 7338

About OncoSil Medical

OncoSil Medical (ASX:OSL) is a global medical device company focused on Interventional Oncology. OncoSil Medical's mission is to improve the outcomes for people living with cancer by utilizing the selected and targeted intratumoural placement of Phosphorous-32 (32P) Microparticles in addition to chemotherapy.

OncoSil Medical has developed OncoSil™ device for the treatment of unresectable locally advanced pancreatic cancer. Its targeted approach enables healthcare professionals to deliver a greater radiation dose directly into the tumour compared to external beam radiotherapy, while sparing surrounding critical organs.

Pancreatic cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with 500,000 new cases detected every year[1]. Since pancreatic cancer is generally diagnosed at a later stage, it has a poor prognosis for long-term survival.

OncoSil™ has received CE Marking approval, providing marketing authorisation in both the EU and the UK. OncoSil™ is designated as a breakthrough device in both Europe and the United States. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with commercial treatments using the device already undertaken in Spain, Italy, Austria, Germany, Greece, Türkiye, Portugal, Israel and the UK.

To learn more, please visit: www.oncosil.com/

1. https://gco.iarc.fr/en

References

[1] Martlı HF, İnsan HO, Altaş M, Erişmiş B, Çayhan V, Ersoy O, Keşkek M, Tez M. Clinicopathological features of patients undergoing surgery for pancreatic cancer with very early postoperative recurrence. World J Gastrointest Surg. 2025 Nov 27;17(11):111202. doi: 10.4240/wjgs.v17.i11.111202. PMID: 41357630; PMCID: PMC12679014.

[2] Gemenetzis G, Groot VP, Blair AB, Laheru DA, Zheng L, Narang AK, Fishman EK, Hruban RH, Yu J, Burkhart RA, Cameron JL, Weiss MJ, Wolfgang CL, He J. Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. Ann Surg. 2019 Aug;270(2):340-347. doi: 10.1097/SLA.0000000000002753. PMID: 29596120; PMCID: PMC6985003.

[3] Hammel P, Lacy J, Portales F, et al: Phase II LAPACT trial of nab-paclitaxel plus gemcitabine for patients with locally advanced pancreatic cancer. 2018 Gastrointestinal Cancers Symposium. Abstract 204.

[4] Chen, Zhiliang MM; Lv, Yongshuang MM; Li, He MD; Diao, Rui MM; Zhou, Jian MD; Yu, Tianwu MD∗. Meta-analysis of FOLFIRINOX-based neoadjuvant therapy for locally advanced pancreatic cancer. Medicine 100(3):p e24068, January 22, 2021. | DOI: 10.1097/MD.0000000000024068

[5] Rombouts SJ, Walma MS, Vogel JA, van Rijssen LB, Wilmink JW, Mohammad NH, van Santvoort HC, Molenaar IQ, Besselink MG. Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer. Ann Surg Oncol. 2016 Dec;23(13):4352-4360. doi: 10.1245/s10434-016-5373-2. Epub 2016 Jul 1. PMID: 27370653; PMCID: PMC5090009.

[6] Ross PJ, Wasan HS, Croagh D et al. Results of a single-arm pilot study of 32P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy. ESMO Open February 2022; 7 (1): 100356